Percona Announces Line-up Of Speakers for Percona Live 2023, the World’s Largest Independent Database Conference
20.4.2023 16:00:00 EEST | Business Wire | Press release
Percona, a leader in enterprise-grade open source database software and services, will host the latest in its annual Percona Live conference series in Denver at the Marriott Tech Center from May 22-24, 2023. Percona Live is the longest-running independent open source database conference, covering a range of database and data management topics including cloud-native deployments, performance improvements, and real-world experience from some of the world’s largest database deployments.
The event will provide three days of hands-on tutorials, breakout sessions, keynote addresses, networking, and socializing with some of the world’s most experienced database professionals. Inspired by the Denver location, this year's event is themed CLIMB. The concept is about reaching peak database performance with open source databases and how Percona serves as a guide to doing so. At the event, industry experts will provide insights around some of the world's most popular databases — MySQL, PostgreSQL, and MongoDB — as well as other open source technologies such as Clickhouse, Vitess, and Kubernetes.
“Open source is essential to driving innovation, which is why we’re excited to bring back Percona Live in person following the success of last year's event in Austin,” commented Ann Schlemmer, CEO of Percona. “Over three days we will bring together the open source community to explore the latest technical advances around databases, approaches to data management and how we can deploy these tools more effectively. The conference enables the community to share their knowledge and experiences with one another to contribute to the future of open source.”
Keynote speakers at this year’s event include:
- Ann Schlemmer, CEO of Percona on The Future of Percona
-
Rachel Stephens, Senior Industry Analyst at RedMonk, As You Wish
Open source databases: a classic tale of true love and high adventure - Peter Zaitsev, Founder of Percona, Unlocking Data Freedom: Harnessing Open Source to Overcome Data Gravity
Additional topics include:
- Database Observability: Through the lens of SRE - Archana Jattigari, Credit Karma
- Why Machine Learning for Automatically Optimizing Databases Doesn't Work - Andy Pavlo, Carnegie Mellon University / OtterTune
- Operating a 120 TB MongoDB dataset on Kubernetes - David Noriega and Eric Fox, Adobe
- No Passwords, Please, We're Pinterest: Secure Identity-Based Authentication for MySQL - Ernie Souhrada, Pinterest
- Reducing Cost and Improving Performance with Data Modeling in Postgres - Charly Batista, Percona
- Upgrading to MySQL 8.0 - Michael Coburn, Percona
- What is the place of AI in SQL querying? - Tatiana Krupenya, DBeaver Corporation
- Pen-testing open source databases (MySQL and PostgreSQL) - Alexander Rubin, AWS
This year’s Percona Live is sponsored by Microsoft, AWS, Oracle, PlanetScale, FerretDB, Datavail, OtterTune, benchAnt, Victoria Metrics, Civo, and DBeaver just to name a few. For more information or to register for the conference, visit: https://www.percona.com/live/conferences
About Percona
Percona is widely recognized as a world-class open source database software, support, and services company. The organization is dedicated to helping businesses make databases and applications run better through a unique combination of expertise and open source software. Percona works with numerous global brands across many industries creating a unified experience to monitor, manage, secure, and optimize database environments on any infrastructure.
Percona equips organizations with the freedom to choose, the freedom to create, and the freedom to make a difference - helping them scale and innovate with speed as they grow. For more information, visit www.percona.com.
Databases run better with Percona.
Percona® is a registered trademark of Percona LLC. All other registered and unregistered trademarks in this document are the sole property of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230420005301/en/
Contact information
Press Contacts
Annabel Lander
Onebite for Percona
percona@onebite.co.uk
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NTT DOCOMO BUSINESS and Chile’s State-owned Copper Company CODELCO Launch a Study and Proof of Concept Aimed at Improving the Efficiency of Remote Copper Mine Operations Using IOWN ® APN6.8.2026 07:30:00 EEST | Press release
NTT DOCOMO BUSINESS, Inc. (formerly NTT Communications Corporation) has launched a study and proof of concept jointly with Corporación Nacional del Cobre de Chile (CODELCO) to progress remote operations at CODELCO’s copper mines using an IOWN® All-Photonics Network (APN).1 This initiative is part of a research project commissioned by Japan’s Ministry of Internal Affairs and Communications.2 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806845222/en/ Conceptual Diagram of the Demonstration To address operational challenges faced by CODELCO’s copper mines, the initiative will connect a copper mine and a remote operations center—approximately 1,500 km apart—via an IOWN APN. It will assess the feasibility of remotely operating heavy machinery using high-capacity, low-latency communication links, enhancing monitoring operations through high-definition video, and implementing a remote operations model. 1. Background Chile is o
FPT Named an OpenAI Select Partner6.8.2026 03:00:00 EEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 01:10:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of ORZEYFUL marks a new chapter for the narcolepsy type 1 community, as we introduce an entirely new class of medicine that will potentially redefine how this disease is managed and howpeople feel on treatment,” said Julie Kim, president and chief executive officer of Takeda. “We are proud to have discovered and developed this orexin treatment innovation and will bring it to adults living with NT1 as quickly as possible.” NT1 is a rare, chronic neurological disease d
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 23:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 17:05:00 EEST | Press release
Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership, and operational excellence with a track record of execution from first-in-human studies through regulatory
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom